Objective: There is a debate regarding the use of diseasespecific versus generic instruments for health-related quality of life (HRQOL) measures. We tested the psychometric properties of HRQOL measures using the Diabetes-39 (D-39) and the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). Methods: This was a cross-sectional study collecting data from 280 patients in Taiwan. Exploratory factor analysis was conducted to evaluate construct validity of the two instruments. Known-groups validity was examined using laboratory indicators (fasting, 2-hour postprandial plasma glucose, and hemoglobin A1c), presence of diabetic complications (retinopathy, nephropathy, neuropathy, diabetic foot disorder, cardiovascular and cerebrovascular disorders), and psychosocial variables (sense of well-being and self-reported diabetes severity). Overall discriminative power of the two instruments was evaluated using the C-statistic. Results: Three distinct factors were extracted through factor analysis. These factors tapped all subscales of the D-39, four physical subscales of the SF-36, and four mental subscales of the SF-36, respectively. Compared with the SF-36, the D-39 demonstrated superior known-groups validity for 2-hour postprandial plasma glucose groups but was inferior for complication groups. Compared with the SF-36, the D-39 discriminated better between self-reported severity known groups, but was inferior between well-being groups. In overall discriminative power, the D-39 discriminated better between laboratory known groups. The SF-36, however, was superior in discriminating between complication known groups. Conclusions: For psychometric properties, the D-39 and the SF-36 were superior to each other in different regards. The combined use of a disease-specific instrument and a generic instrument may be a useful strategy for diabetes HRQOL assessment.
Introduction
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion and/or insulin resistance. The prevalence of diabetes across all age groups worldwide was estimated to be 2.8% in 2000 and projected to be 4.4% by 2030 [1] . The chronic hyperglycemia of diabetes is associated with long-term damage to multiple organ systems, including macrovascular and microvascular diseases. Adults with diabetes have an ageadjusted mortality rate estimated to be twice that of people without diabetes [2] .
Conventional outcome assessment for diabetes relies on laboratory indicators, primarily on hemoglobin A1c (HbA1c) and complications of diseases. The exclusive reliance on clinical outcomes, however, does not necessarily reflect patients' perceptions of their heath [3, 4] . Treatment regimens that require changes of lifestyles and behaviors can influence patients' daily functioning and well-being. Therefore, health-related quality of life (HRQOL) is increasingly used as an outcome indicator alongside traditional biomedical measures.
Several instruments are available for measuring HRQOL in diabetes, including generic and diabetesspecific instruments. Generic instruments are designed to investigate aspects of health that are of universal importance, and allow comparisons of HRQOL among different groups of patients. By contrast, diabetes-specific instruments attempt to capture the specific impact of diabetes on patients' functioning and well-being, and could be more sensitive to small clinically important differences. Reviews have shown that the dimensions covered by diabetes-specific instruments vary, but generally include physical functioning, psychological functioning, social-role fulfillment, diabetes control, and treatment satisfaction [5] [6] [7] . Among instruments, the Medical Outcomes Study 36-Item Short-Form Health Survey (the SF-36) is a commonly used generic instrument for diabetes [8, 9] , while the Diabetes-39 (the D-39) has been demonstrated to have good psychometric properties and can be recommended [5, 7] .
Although various instruments are available to measure HRQOL in diabetes, psychometric evidence does not indicate whether it is preferable to use generic or diabetes-specific instrument individually, or in combination [10] [11] [12] . The knowledge gap in the instrument selection is partly due to incomplete psychometric validation of many instruments during their development. HbA1c, a measure reflecting the longerterm glycemic control, is commonly used as the gold standard to validate the instruments. Evidence of the association between HbA1c and HRQOL scores, however, tends to be weak [13] . It is possible that validation could be improved by including other laboratory indicators (e.g., fasting plasma glucose [FPG] and postprandial plasma glucose [PPG] ) that better account for the impact of fluctuations and acute increase of glycemia (hyperglycemic spikes) on daily functioning [14, 15] .
One study has suggested that FPG and PPG were more sensitive to detect metabolic changes (e.g., hyperglycemia) than HbA1c for type 2 diabetes patients [16] . Other studies reported that postprandial hyperglycemia may contribute more significantly to the development of diabetic complications (especially cardiovascular diseases) than fasting hyperglycemia [14, 17] .
Hyperglycemic symptoms and diabetic complications are major determinants of HRQOL [18, 19] . Other nonglucose indicators that reflect poor control of diabetes, such as renal damage, using serum creatinine (Cr) and glomerular filtration rate (GFR), could also be applied for validation. In addition, the use of psychosocial variables, such as the sense of overall well-being, might help compare generic and diabetesspecific instruments.
The purpose of this study was to compare psychometric properties of a diabetes-specific HRQOL instrument (the D-39) against a generic instrument (the SF-36) using samples collected in Taiwan. Specifically, we evaluated the psychometric properties of both instruments using several clinical and psychosocial variables, including: 1) laboratory indicators: FPG 2-hour PPG, HbA1c, microalbuminuria, Cr, and GFR;
2) complications of diabetes: retinopathy, nephropathy, neuropathy, diabetic foot disorder, cardiovascular, and cerebrovascular diseases; and 3) sense of overall well-being and self-reported diabetes severity. The comparisons of generic versus diabetes-specific instruments will be helpful in guiding instrument selection in HRQOL research and clinical practice.
Methods

Participants and Data Collection
Data were collected from the Taiwan Diabetes Health Survey, an initiative funded by the Taiwan Department of Health (DOH) to systematically translate and adapt HRQOL instruments for diabetes patients. In the first year of this project, we conducted face-to-face interviews to collect data using the D-39 and the SF-36. In total, we interviewed 280 type 1 and type 2 diabetes patients seeking outpatient services in a DOHaffiliated teaching hospital between February and April 2006.
Laboratory and clinical assessments and HRQOL measures were collected at the same time for each patient and tested using the same method for all patients. Laboratory indicators were FPG, 2-hour PPG, HbA1c, microalbuminuria, Cr, and GFR. Diabetes complications were abstracted from medical records. We identified a number of complications, including retinopathy (none vs. background, proliferative, or decreased vision), nephropathy (none vs. proteinuria, or dialysis), neuropathy (none vs. present), diabetic foot disorders (none vs. foot ulceration, sepsis, or amputation), cardiovascular complications (none vs. angina, or previous myocardial infarction or congestive heart failure), and cerebrovascular complications (none vs. transient ischemic attack, or stroke) [20] .
HRQOL Measures
The D-39 is a 39-item instrument that was designed to assess HRQOL for patients with type 1 and type 2 diabetes. This instrument covers the dimensions of energy and mobility (EM), diabetes control (DC), anxiety and worry (AW), social burden (SB), and sexual functioning (SF) [21, 22] . Items are administered using seven response categories, ranging from not affected at all (score = 1) to extremely affected (score = 7). The subscale scores are calculated by summing responses across all items in the same subscale, with high scores representing poor HRQOL. A summary score is further derived from the five subscale scores of the D-39. The Taiwan version of the D-39 (in Chinese) was translated and culturally adapted in 2004 using a standardized approach and has demonstrated good psychometric properties [23] .
The SF-36 is a generic HRQOL instrument measuring a broad range of HRQOL concepts, including physical functioning (PF), role limitations due to physical health problems (RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH). Subscale scores range from 0 to 100, with high scores representing better HRQOL. Two summary scores are also calculated: a physical component score (PCS) and mental component score (MCS), with scores standardized to a normal distribution (mean = 50 and standard deviation [SD] = 10) [24] . The Taiwan version of the SF-36 (in Chinese) was translated in 1996 and has shown acceptable psychometric properties [25] .
Psychometric Analyses
Psychometric properties between the D-39 and the SF-36 were examined using internal consistency, construct validity, known-groups validity, and overall discriminative validity [26] .
The internal consistency of each subscale was assessed by Cronbach's alpha coefficient. Construct validity of the D-39 versus the SF-36 was assessed using exploratory factor analysis, which investigates intercorrelations among subscales of both instruments. Because approximately 3.5% of the subjects (N = 10) were missing on one or two subscale scores and these subjects were not statistically different from those who had no missing values in the variables of age, gender, and clinical measures (e.g., HbA1c, 2-hour PPG, etc.), we simply imputed the missing values using the mean subscale score. According to the rules of thumb (4-10 observations per variables), the use of 280 subjects in this study is sufficient for conducting exploratory factor analysis [27] . We specifically applied the principal factors approach with a promax rotation, assuming extracted factors from the subscales were correlated, for all subscales of the instruments. Homogeneous subscales that measure the same HRQOL construct were assumed to be convergent within the same factor and discriminate themselves from other factors that comprise homogeneous subscales. The number of factors extracted from both instruments was determined by eigenvalues greater than 1 and review of scree plots. Because both instruments measure generic and diabetes-specific concepts of HRQOL, we hypothesized that three factors would be extracted corresponding to a physical impairment construct (mainly physical subscales of the SF-36), a mental health/psychological dissatisfaction (mainly mental subscales of the SF-36), and a diabetes-specific stress factor (mainly the D-39 subscales), respectively.
Known-groups validity of the instruments was examined to assess the extent to which subscales can discriminate between clinically meaningful patient groups, including laboratory diagnosis and diabetic complication groups. Laboratory diagnosis known groups were defined for those patients whose values of laboratory measures were less versus more than the accepted cutoff points: 110 mg/dl for FPG, 140 mg/dl for 2-hour PPG, 7.0% for HbA1c, 1.5 mg/dl for Cr, and 60 ml/min/1.73 m 2 for GFR [28] . GFR is frequently used to estimate the level of kidney function. In this study, the Cockroft-Gault equation was used to estimate GFR, based the patient's Cr, age, gender, and body weight [29] . We used the cutoff of GFR of less than 60 ml/min/1.73 m 2 to define the presence of chronic kidney disease [29] .
Diabetes morbidity known groups were defined for those patients who were diagnosed with versus without complications of retinopathy, nephropathy, neuropathy, diabetic foot diseases, cardiovascular diseases, and cerebrovascular diseases, respectively. A summary indicator-the number of diabetes complicationswas also generated to represent the overall impact of complications. For investigating known-groups validity, we dichotomized this index at the median value for the number of complications. Cohen's effect size (ES) was calculated to measure the magnitude of knowngroup validity (unit: SD) [30] , defined as the differences in subscale scores between known groups (e.g., HbA1c of less vs. more than 7.0%) divided by the pooled SD of both groups.
We also included two psychosocial variables in the comparison of the D-39 and the SF-36: 1) sense of overall well-being; and 2) self-reported diabetes severity. Sense of overall well-being is a single question that was designed to assess patients' overall perception of their quality of life. We hypothesized that this item would discriminate better for generic HRQOL (the SF-36) than for diabetes stress scales (the D-39). Selfreported diabetes severity is a single question that assesses patients' appraisal of diabetes severity. We hypothesized this item would discriminate better for the D-39 than for the SF-36. To investigate knowngroup validity, we dichotomized each of the two measures at their median values.
We assessed overall discriminative validity by the instrument's ability to discriminate patients with laboratory values higher versus lower than the cutoff point as well as those with versus without a specific diabetes complication. Discriminative power was measured by calculating the area under a receiver operator characteristic (ROC) curve (i.e., the C-statistic). An advantage of using the C-statistic is that it can take into account the performance of all subscales simultaneously. The C-statistic ranges from 0.5 (no discriminative power) to 1 (perfect discriminative power). Conventionally, we adopted the values of 0.7 or more, 0.8 or more, and 0.9 or more for the acceptable, good, and excellent discriminative ability, respectively. Separate C-statistics of specific clinical indicators for the D-39 and the SF-36 were compared using a univariate z-test [31, 32] . In this study, all of the analyses were performed using the STATA 9.02 [33] . Table 1 shows the patients' characteristics (N = 280). The mean age was 62.9 years (SD 10.6) and 53% were male. For laboratory measures, mean FPG was 149 mg/dl (SD 44), mean 2-hour PPG was 194 mg/dl (SD 74), and mean HbA1c was 7.5% (SD 1.8). For diabetes complications, 38% had nephropathy, 20% had retinopathy, 17% had diabetic foot disorder, 15% had neuropathy, and 13% and 7% had cardiovascular and cerebrovascular diseases, respectively. For type of treatment, the majority of the subjects (79%) were on lifestyle modification plus oral medication.
Results
Characteristics of Subjects
Scale Reliability
Internal consistency estimated using the Cronbach's alpha exceeded the acceptable level of 0.7 [30] for all subscales of both instruments, except social functioning of the SF-36. Alpha coefficients for the D-39 and the SF-36 subscales ranged from 0.82 to 0.93 and 0.61 to 0.88, respectively.
Construct Validity
The distributions of subscale scores for the SF-36 and the D-39 were normal or near normal (with Skewness and Kurtosis measures around 0 and 3, respectively), which meets the basic requirement of conducting factor analysis [27] . Table 2 shows the construct validity of the D-39 versus the SF-36, examined using exploratory factor analysis. Results of factor analysis suggest that three distinct factors were extracted, each with an eigenvalue of more than 1. The proportion of variance for subscales explained by the extracted factors (i.e., communality) was acceptable, ranging from 0.43 (sexual functioning of the D-39) to 0.88 (energy and mobility of the D-39). After the promax rotation, all subscales of the D-39 loaded on the first factor (diabetes-specific stress). Four subscales of the SF-36 relevant to physical functioning (PF, RP, BP, and GH) loaded on the second factor (physical functioning). Four subscales of the SF-36 relevant to mental health (VT, SF, RE, and MH) aggregated in the third factor (mental health). In addition, a D-39 summary score, PCS and MCS of the SF-36 loaded on the factors of diabetes-specific stress, physical functioning, and mental health, respectively. The intercorrelations among three extracted factors were moderate, with the range between 0.48 (diabetes-specific stress and physical functioning) and 0.58 (diabetes-specific stress and mental health). Taken together, these findings suggest that two instruments may measure different HRQOL constructs. *Classification of body-mass index (BMI) [56] . † Classification of type of diabetes [57] .
Diabetes-Specific versus Generic HRQOL Measures
Known-Groups Validity Table 3 shows known-groups validity investigated using laboratory indicators. After adjusting for age, gender, education background, and diabetes duration, the extent to which subscales discriminated between 2-hour PPG groups was greater than that between FPG and HbA1c groups. In comparisons between instruments, for 2-hour PPG known groups, subscales of the D-39 had better discriminative ability (especially diabetic control, energy and mobility subscales, and a D-39 summary score with effect sizes of 0.33, 0.30, and 0.30, respectively) compared with the SF-36. For FPG and HbA1c known groups, all subscales in both instruments demonstrated ignorable (<0.2) or unexpected signs for effect sizes (i.e., poorer laboratory diagnosis values associated with better HRQOL scores). For Cr known groups, the SF-36 (especially physical subscales) showed greater discriminative ability than the D-39. For example, the effect sizes by the SF-36 PCS, role limitation due to physical problems, and pain subscales for Cr known groups were 0.57, 0.63, and 0.58, respectively. Table 4 shows known-groups validity examined with the individual and summarized measures of diabetes complications. For individual complications, after adjusting for age, gender, education background, and diabetes duration, in general the SF-36 discriminated better than the D-39. This was especially obvious for the physical aspects of the SF-36 for neuropathy, cardiovascular, and cerebrovascular disease groups. Of particular note, the SF-36's physical functioning subscale and PCS demonstrated moderate effect sizes (0.5-0.79) between cardiovascular disease known groups. The SF-36's physical functioning and vitality subscales, as well as PCS demonstrated large effect sizes (Ն0.8) between cerebrovascular disease groups. The SF-36 and the D-39 discriminated equivalently for retinopathy and diabetic foot complication known groups. With respect to a summary complication indicator, results suggest that the SF-36 demonstrates better discriminative ability than the D-39, especially in physical aspects of HRQOL. For example, the effect sizes of the physical functioning subscale and PCS were 0.32 and 0.38, respectively, which were larger than for any subscales of the D-39. Table 5 shows known-groups validity investigated with psychosocial variables. For overall well-being known groups, the SF-36 had slightly better discriminative ability compared with the D-39, especially for mental aspects of HRQOL. For example, the effect sizes of the vitality and mental health subscales of the SF-36 were 0.64 and 0.60, which were higher than for any of the D-39 subscales. In contrast, for self-reported diabetes severity known groups, the D-39 demon- 
strated slightly better discriminated ability than the SF-36. For example, the effect sizes for the energy and mobility subscale and a D-39 summary score were 0.9 and 0.88, which were higher than for any subscales of the SF-36.
Overall Discriminative Validity
The overall discriminative power of the D-39 and the SF-36 using the indicators of laboratory diagnosis and complication is shown in Table 6 . The D-39 demonstrated slightly higher C-statistics than the SF-36 (either for eight subscales or for two component scales) for glucose indicators, including FPG, 2-hour PPG and HbA1c. The C-statistics for the SF-36 were equivalent to or slightly higher than the D-39 for the Cr and GFR indicators. After adjusting for age, gender, education, and diabetes duration, the D-39 demonstrated significantly a higher C-statistic for 2-hour PPG than the SF-36's two component scores (0.70 vs. 0.63; P < 0.05).
For complications, the SF-36 revealed higher C-statistics than the D-39 across all types of conditions, except neuropathy. Especially, for cardiovascular disease known groups, the C-statistic of the SF-36 eight subscales was significantly higher than that of the D-39 five subscales (0.76 vs. 0.66; P < 0.05). Likewise, for the summary complication known groups, the C-statistics of the SF-36 eight subscales and two component scales were significantly higher than those of D-39 subscales (0.72 vs. 0.62 and 0.72 vs. 0.62, respectively; all comparisons with P < 0.05). After adjusting for age, gender, education, and diabetes duration, the SF-36 demonstrated equivalent or slightly higher C-statistics than the D-39 (all comparisons with P > 0.05).
For psychosocial variables, the D-39 and SF-36 demonstrated similar overall discriminative ability between the overall well-being groups and selfreported severity groups (all comparisons with P > 0.05). Figure 1 shows the association of HRQOL and four types of diabetes treatments-lifestyle modification alone, lifestyle modification plus oral medication (LO), lifestyle modification plus insulin (LI), and lifestyle modification, oral medication plus insulin (LOI). For the D-39, after adjusting for age, gender, education, diabetes duration, and complications, subjects treated with the LOI were associated with poorer HRQOL in all subscales (except sexual functioning) than the LI group, followed by the LO group. Subjects treated by lifestyle modification alone showed the best HRQOL. Of particular note, contrasting to those receiving lifestyle modification alone, subjects in the LOI group had large (effect size: Ն0.8) and moderate (effect size: 0.5-0.79) impact on the energy/mobility and diabetes control, respectively.
Treatment Effect and HRQOL Measures
For the SF-36 PCS, compared with those receiving lifestyle modification alone, subjects in the LOI group had greater impact on HRQOL (moderate effect size) than those in either the LI or the LO group (small effect size). By contrast, type of treatment had ignorable impact (effect size of less than 0.2) on the SF-36 MCS.
Discussion
In this study, we compared psychometric properties of a diabetes-specific HRQOL instrument (the D-39) versus a generic instrument (the SF-36) using samples collected in Taiwan. Our study differed from previous studies of this type in that we evaluated the HRQOL measures against a variety of laboratory and clinical indicators (FPG, 2-hour PPG, HbA1c, microalbuminuria, Cr, GFR, and diabetes complications) and psychosocial variables (sense of overall well-being and self-reported diabetes severity), and applying different psychometric methods.
Construct validity suggests that the D-39 and SF-36 may measure different HRQOL construct. Three distinct factors were extracted through factor analysis, each tapping all subscales of the D-39, four physical subscales of the SF-36, and four mental subscales of the SF-36, respectively. Known-groups validity revealed that the D-39 was superior to the SF-36 for discriminating 2-hour PPG and HbA1c known groups. There were larger differences seen for 2-hour PPG groups than for HbA1c groups. For complications known groups, however, the subscales of the SF-36 generally discriminated better than the D-39. Compared with the SF-36, the D-39 discriminated better between the self-reported severity groups, but was inferior for sense of well-being groups. For overall discriminative power, the D-39 discriminated better between laboratory groups. In contrast, the SF-36 discriminated better between complication groups.
Previous studies have used HbA1c as the glycemic control indicator to validate HRQOL measures. Evidence, however, is mixed regarding the association of HbA1c with HRQOL. Although some studies have suggested that good glycemic control was associated with better HRQOL [34] [35] [36] , other studies have not [4, 12, [37] [38] [39] . Although the inconsistent findings may in part be attributed to the use of different HRQOL instruments (especially, generic vs. disease-specific) [13] , another reason may be that clinical indicators such as HbA1c are relatively insensitive to the differences in HRQOL measures.
Basically, HbA1c is an integrated summary of blood glucose levels during the preceding 2 to 3 months. By contrast, 2-hour PPG captures the peaks and troughs in glucose concentrations that represent short-term fluctuations in metabolic control. Epidemiologic Table 6 Overall performance of the D-39 and SF-36 examined using the C-statistic* PCS, physical component score; MCS, mental component score; PF, physical functioning; RP, role limitations due to physical problems; BP, bodily pain; GH, general health perceptions;VT, vitality; SF, social functioning; RE, role limitations due to emotional problems; MH, mental health.
studies have suggested that normal HbA1c levels could be associated with postprandial hyperglycemia, leading to a substantially increased risk of death from macrovascular diseases [14, 40, 41] , especially for cardiovascular complications [17, 42, 43] . In most instances, PPG levels increase before and faster than FPG [44] [45] [46] . As a result, increased postprandial glycemia is related to greater risk than fasting hyperglycemia for the development of cardiovascular diseases and all-cause mortality [42, 47, 48] . Together with our results, this suggests the use of 2-hour PPG in addition to HbA1c to test the validity of diabetes HRQOL measures. In contrast to blood sugar abnormalities, diabetes complications can cause a significant impact on HRQOL [3, 49, 50] . For people with poor glycemic control, the major risk is the development of chronic problems that affect multiple organ systems. Lloyd et al. found that patients with more diabetes complications (particularly three or more complications) tended to report poor HRQOL [51] . Several studies have shown that the subscales of HRQOL measures [11, 21, 52] (typically physical HRQOL [53] ) can discriminate the presence and absence of diabetes complications. Consistent with other studies [37, 49] , our results support the value of cardiovascular and cerebrovascular diseases known groups. Interestingly, this was not true for retinopathy and nephropathy. It is possible that changes in retinal blood vessels or proteinuria (typically microalbuminuria) may appear early in diabetes and may not be associated with symptoms for many years.
We were able to compare known-groups validity using laboratory and clinical measures, and found that given the same instruments, effect sizes for laboratory measures were smaller than for diabetes complications. This may be due to the fact that 1) not all people with diabetes suffer from complications; and 2) clinical symptoms (e.g., hypoglycemia) and events (e.g., stroke) are more evident to patients than laboratory abnormalities.
It has long been debated whether generic or disease-specific instruments should be used to assess HRQOL in patients with diabetes. A study by Hirsch et al. using factor analysis has demonstrated three factors can be extracted from the measures using the SF-36, D-39, and Diabetes Treatment Satisfaction Questionnaire [6] , each factor representing a distinct concept. This would suggest that generic and diseasespecific instruments may measure different HRQOL constructs. Previous studies [21, 22] also reported that the correlations of the D-39 and SF-36 subscale scores were at most moderate, even for among homogenous subscales, suggesting the constructs in two instruments were not completely equivalent. Taken together, these findings suggest that generic and disease-specific instruments for diabetes measures should be complementary, rather than substitutive. This makes intuitive sense because disease-specific measures are designed primarily to capture the influence of diabetic control, beyond the impact of morbidities. By contrast, the generic instruments have the advantage of detecting HRQOL differences influenced by diabetes complications, which may be confounded by symptoms associated with other conditions, leading to better discriminative capability than disease-specific measures.
Although the combined use of generic and diseasespecific measures may offer a comprehensive picture for diabetes HRQOL measures, there are still many unanswered questions. An important issue is how to reduce the number of items while retaining measurement precision. The application of item response theory (IRT) for instrument development may be able to provide better answers [54, 55] . The main advantage of IRT is to link and equate items across instruments on the same metric, which is helpful in generating an item pool that contains items with a wide range of item properties. Thus, IRT allows researcher to tailor an instrument that matches the latent trait of HRQOL constructs for individual patients. To this point, however, there have been few applications of IRT to diabetes HRQOL measures.
There are a number of limitations to this study. First, the generalizability of our results may be limited because our samples were collected from a single center in Taiwan. Second, we did not examine testretest and responsiveness of both instruments. The interpretation of the score changes (responsiveness) for HRQOL instruments is important for clinical practice. As validation of measures is an ongoing process, future studies should examine these properties together with diabetes specificity of measures, compare the impact of these outcomes in diabetes with other conditions, and examine the minimal clinically important difference for interpreting meaningful change.
Conclusions
We demonstrated that for diabetes HRQOL assessment, a diabetes-specific (the D-39) measure was not definitely superior to a generic one (the SF-36). Rather each instrument had some advantages over the other. The D-39 and the SF-36 for HRQOL measures appear to be complementary rather than substitutive. The use of disease-specific and generic instruments together may be the best strategy for measurement of HRQOL in diabetes. Further studies are suggested to explore the use of IRT explicitly to link items across different instruments.
